The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Paul A. Gurbel

Sinai Center for Thrombosis Research

Cardiac Catherization Laboratories

2401 W. Belvedere Ave

Baltimore

[email]@lifebridgehealth.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Sinai Center for Thrombosis Research, Cardiac Catherization Laboratories, 2401 W. Belvedere Ave, Baltimore. 2011 - 2012
  • Cardiac Catheterization Laboratory, Sinai Center for Thrombosis Research, 2401 West Belvedere Avenue, Baltimore, USA;. 2012
  • Sinai Center for Thrombosis Research, Sinai Hospital, Baltimore, MD 21215, USA. 2002 - 2011

References

  1. Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel. Jeong, Y.H., Tantry, U.S., Gurbel, P.A. Expert. Opin. Pharmacother (2012) [Pubmed]
  2. Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps? Gurbel, P.A., Roe, M.T., Jakubowski, J.A., Shah, S., Erlinge, D., Goodman, S.G., Huber, K., Chan, M.Y., Cornel, J.H., Tantry, U.S., Ohman, E.M. Thromb. Haemost. (2012) [Pubmed]
  3. High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype. Jeong, Y.H., Park, Y., Bliden, K.P., Tantry, U.S., Gurbel, P.A. Heart (2012) [Pubmed]
  4. Peri-operative platelet function testing: The potential for reducing ischaemic and bleeding risks. Gurbel, P.A., Mahla, E., Tantry, U.S. Thromb. Haemost. (2011) [Pubmed]
  5. Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. Gurbel, P.A., Tantry, U.S. Thromb. Haemost. (2011) [Pubmed]
  6. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Gurbel, P.A., Shuldiner, A.R., Bliden, K.P., Ryan, K., Pakyz, R.E., Tantry, U.S. Am. Heart J. (2011) [Pubmed]
  7. Vorapaxar: a novel protease-activated receptor-1 inhibitor. Gurbel, P.A., Jeong, Y.H., Tantry, U.S. Expert. Opin. Investig. Drugs (2011) [Pubmed]
  8. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Gurbel, P.A., Bliden, K.P., Butler, K., Antonino, M.J., Wei, C., Teng, R., Rasmussen, L., Storey, R.F., Nielsen, T., Eikelboom, J.W., Sabe-Affaki, G., Husted, S., Kereiakes, D.J., Henderson, D., Patel, D.V., Tantry, U.S. Circulation (2010) [Pubmed]
  9. Genotyping: one piece of the puzzle to personalize antiplatelet therapy. Gurbel, P.A., Tantry, U.S., Shuldiner, A.R., Kereiakes, D.J. J. Am. Coll. Cardiol. (2010) [Pubmed]
  10. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. Gurbel, P.A., Bliden, K.P., Antonino, M.J., Stephens, G., Gretler, D.D., Jurek, M.M., Pakyz, R.E., Shuldiner, A.R., Conley, P.B., Tantry, U.S. J. Thromb. Haemost. (2010) [Pubmed]
  11. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Gurbel, P.A., Bliden, K.P., Navickas, I.A., Mahla, E., Dichiara, J., Suarez, T.A., Antonino, M.J., Tantry, U.S., Cohen, E. Am. Heart J. (2010) [Pubmed]
  12. Ticagrelor for the treatment of arterial thrombosis. Gurbel, P.A., Kereiakes, D.J., Tantry, U.S. Expert. Opin. Pharmacother (2010) [Pubmed]
  13. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Gurbel, P.A., Bliden, K.P., Butler, K., Tantry, U.S., Gesheff, T., Wei, C., Teng, R., Antonino, M.J., Patil, S.B., Karunakaran, A., Kereiakes, D.J., Parris, C., Purdy, D., Wilson, V., Ledley, G.S., Storey, R.F. Circulation (2009) [Pubmed]
  14. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Gurbel, P.A., Antonino, M.J., Tantry, U.S. Expert. Opin. Drug. Metab. Toxicol (2009) [Pubmed]
  15. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. Gurbel, P.A., Bliden, K.P., Saucedo, J.F., Suarez, T.A., DiChiara, J., Antonino, M.J., Mahla, E., Singla, A., Herzog, W.R., Bassi, A.K., Hennebry, T.A., Gesheff, T.B., Tantry, U.S. J. Am. Coll. Cardiol. (2009) [Pubmed]
  16. Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease. Gurbel, P.A., Tantry, U.S. Curr. Treat. Options. Cardiovasc. Med (2009) [Pubmed]
  17. The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. Gurbel, P.A., Bliden, K.P., Kreutz, R.P., Dichiara, J., Antonino, M.J., Tantry, U.S. Platelets (2009) [Pubmed]
  18. Response variability and the role of platelet function testing. Gurbel, P.A., Mahla, E., Antonino, M.J., Tantry, U.S. J. Invasive. Cardiol (2009) [Pubmed]
  19. Antiplatelet resistance--fact or myth?. Gurbel, P.A., Tantry, U.S. Am. Heart. Hosp. J (2009) [Pubmed]
  20. Prasugrel, a third generation thienopyridine and potent platelet inhibitor. Gurbel, P.A., Tantry, U.S. Curr. Opin. Investig. Drugs (2008) [Pubmed]
  21. Antiplatelet treatment of cardiovascular disease: a translational research perspective. Gurbel, P.A., Antonino, M.J., Tantry, U.S. Pol. Arch. Med. Wewn. (2008) [Pubmed]
  22. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Gurbel, P.A., Antonino, M.J., Bliden, K.P., Dichiara, J., Suarez, T.A., Singla, A., Tantry, U.S. Platelets (2008) [Pubmed]
  23. The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. Gurbel, P.A., Tantry, U.S. J. Interv. Cardiol (2008) [Pubmed]
  24. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Gurbel, P.A., Kreutz, R.P., Bliden, K.P., DiChiara, J., Tantry, U.S. Am. Heart J. (2008) [Pubmed]
  25. Diagnostics for aspirin resistance. Gurbel, P.A., Bilden, K.P., Tantry, U.S. Molecular. Diagnosis. &. Therapy (2008) [Pubmed]
  26. Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. Gurbel, P.A., Bliden, K.P., Cohen, E., Navickas, I.A., Singla, A., Antonino, M.J., Fissha, M., Kreutz, R.P., Bassi, A.K., Tantry, U.S. Blood Coagul. Fibrinolysis (2008) [Pubmed]
  27. Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. Gurbel, P.A., DiChiara, J., Tantry, U.S. Am. J. Cardiol. (2007) [Pubmed]
  28. Clopidogrel resistance? Gurbel, P.A., Tantry, U.S. Thromb. Res. (2007) [Pubmed]
  29. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Gurbel, P.A., Bliden, K.P., Etherington, A., Tantry, U.S. Thromb. Res. (2007) [Pubmed]
  30. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Gurbel, P.A., Bliden, K.P., Guyer, K., Aggarwal, N., Tantry, U.S. Thromb. Res. (2007) [Pubmed]
  31. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Gurbel, P.A., Bliden, K.P., DiChiara, J., Newcomer, J., Weng, W., Neerchal, N.K., Gesheff, T., Chaganti, S.K., Etherington, A., Tantry, U.S. Circulation (2007) [Pubmed]
  32. Clopidogrel resistance: implications for coronary stenting. Gurbel, P.A., Lau, W.C., Bliden, K.P., Tantry, U.S. Curr. Pharm. Des. (2006) [Pubmed]
  33. Drug insight: Clopidogrel nonresponsiveness. Gurbel, P.A., Tantry, U.S. Nature Clinical Practice. Cardiovascular Medicine (2006) [Pubmed]
  34. Aspirin and clopidogrel resistance: consideration and management. Gurbel, P.A., Tantry, U.S. J. Interv. Cardiol (2006) [Pubmed]
  35. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. Gurbel, P.A., Bliden, K.P., Tantry, U.S. J. Am. Coll. Cardiol. (2006) [Pubmed]
  36. The platelet-related effects of tenecteplase versus alteplase versus reteplase. Gurbel, P.A., Hayes, K., Bliden, K.P., Yoho, J., Tantry, U.S. Blood Coagul. Fibrinolysis (2005) [Pubmed]
  37. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Gurbel, P.A., Bliden, K.P., Zaman, K.A., Yoho, J.A., Hayes, K.M., Tantry, U.S. Circulation (2005) [Pubmed]
  38. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. Gurbel, P.A., Bliden, K.P., Hayes, K.M., Yoho, J.A., Herzog, W.R., Tantry, U.S. J. Am. Coll. Cardiol. (2005) [Pubmed]
  39. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. Gurbel, P.A., Bliden, K.P., Guyer, K., Cho, P.W., Zaman, K.A., Kreutz, R.P., Bassi, A.K., Tantry, U.S. J. Am. Coll. Cardiol. (2005) [Pubmed]
  40. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. Gurbel, P.A., Bliden, K.P., Samara, W., Yoho, J.A., Hayes, K., Fissha, M.Z., Tantry, U.S. J. Am. Coll. Cardiol. (2005) [Pubmed]
  41. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Gurbel, P.A., Samara, W.M., Bliden, K.P. Platelets (2004) [Pubmed]
  42. Platelet activation in myocardial ischemic syndromes. Gurbel, P.A., Bliden, K.P., Hayes, K.M., Tantry, U. Expert. Rev. Cardiovasc. Ther (2004) [Pubmed]
  43. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Gurbel, P.A., Cummings, C.C., Bell, C.R., Alford, A.B., Meister, A.F., Serebruany, V.L. Am. Heart J. (2003) [Pubmed]
  44. Durability of platelet inhibition by clopidogrel. Gurbel, P.A., Bliden, K.P. Am. J. Cardiol. (2003) [Pubmed]
  45. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Gurbel, P.A., Bliden, K.P., Hiatt, B.L., O'Connor, C.M. Circulation (2003) [Pubmed]
  46. Platelet activation after stenting with heparin-coated versus noncoated stents. Gurbel, P.A., Bliden, K.P. Am. Heart J. (2003) [Pubmed]
  47. A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity. Gurbel, P.A., Bliden, K.P. Platelets (2003) [Pubmed]
  48. The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. Gurbel, P.A., Bliden, K.P. Thromb. Res. (2003) [Pubmed]
  49. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. Gurbel, P.A., Malinin, A.I., Callahan, K.P., Serebruany, V.L., O'Connor, C.M. Am. J. Cardiol. (2002) [Pubmed]
  50. Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. Gurbel, P.A., Callahan, K.P., Malinin, A.I., Serebruany, V.L., Gillis, J. J. Invasive. Cardiol (2002) [Pubmed]
  51. Correction of a saphenous vein graft to coronary vein anastamosis by selective retrograde coil-induced occlusion to arterialize the native vein. Gurbel, P.A., Austin, B., Cho, P.W., Sequeira, A.J. Catheter. Cardiovasc. Interv (2002) [Pubmed]
  52. Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy). Gurbel, P.A., Galbut, B., Bliden, K.P., Bahr, R.D., Roe, M.T., Serebruany, V.L., Gibler, W.B., Christenson, R.H., Ohman, E.M. J. Thromb. Thrombolysis (2002) [Pubmed]
 
WikiGenes - Universities